In the News

2014/02/10 Press Release: Abnova introduces its medical service laboratory partner Wellconn Genomics™ at Taiwan Society of Perinatology Meeting, Kaoshung, Taiwan.
2014/02/11 Press Release: Wellconn Genomics introduces ACTN4 tissue biomarker immunohistochemical and FISH probe staining for lung adenocarcinoma prognosis.
2014/04/08 Press Release: Wellconn Genomics introduces Prenatal BoBs™ (BACs-on-Beads) CE IVD service.
2014/05/03 Press Release: Wellconn Genomics launches its official website.
2014/05/15 Press Release: Abnova Partners with Wellconn Genomics™ to Provide Medical Laboratory Services.
2014/06/19 Conference: Wellconn and Abnova co-host Prenatal Diagnostic Seminar in Taipei on July 18th.
2014/06/19 Conference: Wellconn and Abnova co-host Prenatal Diagnostic Seminar in Kaoshung on July 19th.
2015/02/02 Press Release: Abnova provides circulating tumor cell isolation and analysis services to Taipei Veteran General Hospital (TVGH), Tri-Service General Hospital, and National Taiwan University Hospital (NTUH).
2016/04/06 Press Release: Cell-Surface Vimentin (CSV) proprietary monoclonal antibody utilized for circulating tumor cell capture and detection.
2016/06/23 Press Release: Wellconn Genomics (Taiwan) successfully passed Taipei City Government Department of Health inspection.
2017/04/12 Press Release: Wellconn Genomics established as a third party clinical laboratory in Dongguan, China.
2017/05/05 Press Release: mutaFISH™ probes utilized for in situ mutation detection in circulating tumor cells.
2017/07/21 Press Release: Abnova (Dongguan) Diagnostics’CytoQuest™ CR System gains Class I in vitro diagnostics EMC & Safety CFDA approval in China.
2017/08/22 Press Release: Abnova gains precision medicine momentum.
2017/09/11 Press Release: Abnova Enters Third-Party Diagnostic Market in China.
2017/10/17 Conference: Invited Talk at Shin Kong Wu Ho-Su Memorial Hospital.
2018/01/11 Press Release: Abnova developed and submitted RoHS compatible CytoQuest™ CR System for SGS and CE-IVD certification.
2018/02/08 Press Release: Abnova Gained Japan PMDA Permission to Advances ACTN4 In Vitro Diagnostic (IVD) Biomarker for Lung Adenocarcinoma into Clinical Trial in Japan.
2018/05/21 Press Release: Abnova Expands its SELECT™ Non-Invasive Fetal Cell Liquid Biopsy Platform with Clinical Validation Study in Japan Sanno Hospital.
2018/06/26 Press Release: Abnova & Yourgene Collaborate to Accelerate Next Generation Sequencing Capability and Analysis of Circulating Tumor Cell and Circulating Fetal Cell in Taiwan.
2018/07/31 Press Release: Abnova Launches Cell-Based, Non-Invasive Liquid Biopsy of Circulating Endothelial Progenitor Cells (EPC) Targeting Healthy and Anti-Aging Markets.
2018/09/10 Press Release: Abnova T-cell Therapy Demonstrated Efficacy against Large Solid Tumors in Preclinical Studies.
2018/10/09 Press Release: Abnova & BioView Successfully Developed All-in-One Imaging System and Artificial Intelligence (AI) Solution for Identification of Circulating Tumor and Fetal Cells (CTCs and CFCs).
2019/01/28 Press Release: Abnova & Nippon Kayaku Signed Exclusive ACTN4 Supply and Commercialization Agreement for Lung Cancer IVD Market in Japan.

©2020 Wellconn Genomics 懷慷醫事檢驗所. All rights reserved.